Hemostemix Inc (HMTXF)

[CA Market News]

Hemostemix Leadership Attending Abundance360 Summit

March 9, 2026 11:23 AM
Newsfile

Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026 Abundance360 Summit in Los Angeles this week.

Founded by futurist and entrepreneur Peter H. Diamandis, the annual Abundance360 Summit convenes leading entrepreneurs, and investors, working at the frontiers of biotechnology, artificial intelligence, longevity science, and other exponential technologies expected to reshape human health.

At this event, Hemostemix Inc. is describing ACP-01 (VesCell), as a regenerative treatment designed to increase health span via microvascular circulation, as it drives the growth of new blood vessels where the body signals that need. Improved tissue perfusion and vascular regeneration are increasingly recognized as fundamental drivers of healthy aging. ACP-01's ability to restore circulation has been detailed in 11 peer-reviewed publications studying patients with conditions including angina, ischemic cardiomyopathy (ICM), dilated cardiomyopathy (DCM), and chronic limb-threatening ischemia (CLTI).

Mr. Smeenk and Mr. Lacey will meet with investors and longevity participants to discuss the opportunity to join Hemostemix as shareholders in its commercialization stage in Florida and The Bahamas.

"Abundance360 is an incredible event," said Thomas Smeenk, President and CEO of Hemostemix. "76% and 15% of Fountain Life members were found to have stage 1, or stage 2-3 coronary artery disease, respectively, after going trough the Fountain Life examinations. Peter Diamandis' motto 'do not die from something stupid' is obvious. The conversations about commercialization in Florida and The Bahamas are generating significant interest, as it is based on 498 treatments, seven clinical trials, and statistically significant improvement in heart function and circulation, which is the key to longevity," Smeenk said.

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO EM:?www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287763

Original: Hemostemix Leadership Attending Abundance360 Summit